These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 18807709)

  • 1. Manage infusion reactions from cetuximab.
    Becze E
    ONS Connect; 2008 Sep; 23(9):18-9. PubMed ID: 18807709
    [No Abstract]   [Full Text] [Related]  

  • 2. Managing drug infusion reactions: focus on cetuximab monoclonal antibody therapy.
    Wilkes G
    Clin J Oncol Nurs; 2008 Jun; 12(3):530-2. PubMed ID: 18515254
    [No Abstract]   [Full Text] [Related]  

  • 3. A patient on targeted therapy: cetuximab.
    Vogel WH
    Oncology (Williston Park); 2006 Sep; 20(10 Suppl Nurse Ed):25-7. PubMed ID: 18153976
    [No Abstract]   [Full Text] [Related]  

  • 4. An infusion reaction to cetuximab.
    Waxman ES
    Oncology (Williston Park); 2011 Apr; 25(4 Suppl Nurse Ed):38-41. PubMed ID: 25391206
    [No Abstract]   [Full Text] [Related]  

  • 5. The impact of infusion reactions on oncology patients and clinicians in the inpatient and outpatient practice settings: oncology nurses' perspectives.
    Colwell HH; Mathias SD; Ngo NH; Gitlin M; Lu ZJ; Knoop T
    J Infus Nurs; 2007; 30(3):153-60. PubMed ID: 17505216
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Management of severe infusion reactions after cetuximab.
    Cerman J; Melichar B; Cermanova M; Solichova D
    Acta Oncol; 2008; 47(8):1609-11. PubMed ID: 18607870
    [No Abstract]   [Full Text] [Related]  

  • 7. Cetuximab-associated infusion reactions: pathology and management.
    Patel DD; Goldberg RM
    Oncology (Williston Park); 2006 Oct; 20(11):1373-82; discussion 1382, 1392-4, 1397. PubMed ID: 17112000
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Incidence of infusion reactions induced by cetuximab chemotherapy].
    Maeda T; Tatematsu M; Muro K
    Gan To Kagaku Ryoho; 2011 Jun; 38(6):963-6. PubMed ID: 21677487
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cetuximab: adverse event profile and recommendations for toxicity management.
    Thomas M
    Clin J Oncol Nurs; 2005 Jun; 9(3):332-8. PubMed ID: 15973844
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Managing premedications and the risk for reactions to infusional monoclonal antibody therapy.
    Chung CH
    Oncologist; 2008 Jun; 13(6):725-32. PubMed ID: 18586928
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Infusion reactions triggered by monoclonal antibodies treating solid tumors.
    Carney PH; Ollom CL
    J Infus Nurs; 2008; 31(2):74-83. PubMed ID: 18344767
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Infusion reactions: diagnosis, assessment, and management.
    Vogel WH
    Clin J Oncol Nurs; 2010 Apr; 14(2):E10-21. PubMed ID: 20350882
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Managing cetuximab hypersensitivity-infusion reactions: incidence, risk factors, prevention, and retreatment.
    George TJ; Laplant KD; Walden EO; Davis AB; Riggs CE; Close JL; George SN; Lynch JW
    J Support Oncol; 2010; 8(2):72-7. PubMed ID: 20464886
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Management and preparedness for infusion and hypersensitivity reactions.
    Lenz HJ
    Oncologist; 2007 May; 12(5):601-9. PubMed ID: 17522249
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Diagnose, assess, and manage infusion reactions.
    Becze E
    ONS Connect; 2010 Jul; 25(7):12-3. PubMed ID: 20669809
    [No Abstract]   [Full Text] [Related]  

  • 16. Cetuximab infusion reactions: French pharmacovigilance database analysis.
    Grandvuillemin A; Disson-Dautriche A; Miremont-Salamé G; Fourrier-Reglat A; Sgro C;
    J Oncol Pharm Pract; 2013 Jun; 19(2):130-7. PubMed ID: 23154574
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Infusion-related and hypersensitivity reactions of monoclonal antibodies used to treat colorectal cancer--identification, prevention, and management.
    Kang SP; Saif MW
    J Support Oncol; 2007 Oct; 5(9):451-7. PubMed ID: 18019853
    [No Abstract]   [Full Text] [Related]  

  • 18. Fatal infusion reaction to cetuximab: the need for predictive risk factors and safer patient selection.
    Tronconi MC; Sclafani F; Rimassa L; Carnaghi C; Personeni N; Santoro A
    J Clin Oncol; 2011 Aug; 29(23):e680-1. PubMed ID: 21690469
    [No Abstract]   [Full Text] [Related]  

  • 19. Clinical issues in the administration of an anti-epidermal growth factor receptor monoclonal antibody, IMC-C225.
    Hollywood E
    Semin Oncol Nurs; 2002 May; 18(2 Suppl 2):30-5. PubMed ID: 12053862
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of a protocol to minimize hypersensitivity reactions with asparaginase administration.
    Bryant R
    J Intraven Nurs; 2001; 24(3):169-73. PubMed ID: 11530362
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.